 | • レポートコード：GIR-2104Z05400 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、ファブリー病治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。ファブリー病治療の種類別市場規模（酵素補充療法、代替療法）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・ファブリー病治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Amicus therapeutics、Takeda、Genzyme-Sanofi、Protalix、Sanofi-Aventis LLC、Novartis Pharmaceuticals、Pfizer、Bristol-Myers Squibb Company、GlaxoSmithKline plc、Amgen Inc.、Teva pharmaceutical Industries Ltd.、Merc & Co.、AbbVie Inc.、Takeda Pharmaceutical Co. Ltd.、Green Cross Corp. ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：酵素補充療法、代替療法 ・用途別分析2016年-2026年：病院、診療所、その他 ・ファブリー病治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・ファブリー病治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・ファブリー病治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・ファブリー病治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・ファブリー病治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Fabry Disease Therapeutic market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Fabry Disease Therapeutic size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Fabry Disease Therapeutic market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Fabry Disease Therapeutic market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Enzyme Replacement Therapy
Alternative therapies
Market segment by Application, can be divided into
Hospitals
Clinics
Other
Market segment by players, this report covers
Amicus therapeutics
Takeda
Genzyme-Sanofi
Protalix
Sanofi-Aventis LLC
Novartis Pharmaceuticals
Pfizer
Bristol-Myers Squibb Company
GlaxoSmithKline plc
Amgen Inc.
Teva pharmaceutical Industries Ltd.
Merc & Co.
AbbVie Inc.
Takeda Pharmaceutical Co. Ltd.
Green Cross Corp.
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Fabry Disease Therapeutic
1.2 Classification of Fabry Disease Therapeutic by Type
1.2.1 Overview: Global Fabry Disease Therapeutic Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Fabry Disease Therapeutic Revenue Market Share by Type in 2020
1.2.3 Enzyme Replacement Therapy
1.2.4 Alternative therapies
1.3 Global Fabry Disease Therapeutic Market by Application
1.3.1 Overview: Global Fabry Disease Therapeutic Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Fabry Disease Therapeutic Market Size & Forecast
1.5 Global Fabry Disease Therapeutic Market Size and Forecast by Region
1.5.1 Global Fabry Disease Therapeutic Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Fabry Disease Therapeutic Market Size by Region, (2016-2021)
1.5.3 North America Fabry Disease Therapeutic Market Size and Prospect (2016-2026)
1.5.4 Europe Fabry Disease Therapeutic Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Fabry Disease Therapeutic Market Size and Prospect (2016-2026)
1.5.6 South America Fabry Disease Therapeutic Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Fabry Disease Therapeutic Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Fabry Disease Therapeutic Market Drivers
1.6.2 Fabry Disease Therapeutic Market Restraints
1.6.3 Fabry Disease Therapeutic Trends Analysis
2 Company Profiles
2.1 Amicus therapeutics
2.1.1 Amicus therapeutics Details
2.1.2 Amicus therapeutics Major Business
2.1.3 Amicus therapeutics Fabry Disease Therapeutic Product and Solutions
2.1.4 Amicus therapeutics Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Amicus therapeutics Recent Developments and Future Plans
2.2 Takeda
2.2.1 Takeda Details
2.2.2 Takeda Major Business
2.2.3 Takeda Fabry Disease Therapeutic Product and Solutions
2.2.4 Takeda Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Takeda Recent Developments and Future Plans
2.3 Genzyme-Sanofi
2.3.1 Genzyme-Sanofi Details
2.3.2 Genzyme-Sanofi Major Business
2.3.3 Genzyme-Sanofi Fabry Disease Therapeutic Product and Solutions
2.3.4 Genzyme-Sanofi Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Genzyme-Sanofi Recent Developments and Future Plans
2.4 Protalix
2.4.1 Protalix Details
2.4.2 Protalix Major Business
2.4.3 Protalix Fabry Disease Therapeutic Product and Solutions
2.4.4 Protalix Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Protalix Recent Developments and Future Plans
2.5 Sanofi-Aventis LLC
2.5.1 Sanofi-Aventis LLC Details
2.5.2 Sanofi-Aventis LLC Major Business
2.5.3 Sanofi-Aventis LLC Fabry Disease Therapeutic Product and Solutions
2.5.4 Sanofi-Aventis LLC Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Sanofi-Aventis LLC Recent Developments and Future Plans
2.6 Novartis Pharmaceuticals
2.6.1 Novartis Pharmaceuticals Details
2.6.2 Novartis Pharmaceuticals Major Business
2.6.3 Novartis Pharmaceuticals Fabry Disease Therapeutic Product and Solutions
2.6.4 Novartis Pharmaceuticals Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Novartis Pharmaceuticals Recent Developments and Future Plans
2.7 Pfizer
2.7.1 Pfizer Details
2.7.2 Pfizer Major Business
2.7.3 Pfizer Fabry Disease Therapeutic Product and Solutions
2.7.4 Pfizer Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Pfizer Recent Developments and Future Plans
2.8 Bristol-Myers Squibb Company
2.8.1 Bristol-Myers Squibb Company Details
2.8.2 Bristol-Myers Squibb Company Major Business
2.8.3 Bristol-Myers Squibb Company Fabry Disease Therapeutic Product and Solutions
2.8.4 Bristol-Myers Squibb Company Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
2.9 GlaxoSmithKline plc
2.9.1 GlaxoSmithKline plc Details
2.9.2 GlaxoSmithKline plc Major Business
2.9.3 GlaxoSmithKline plc Fabry Disease Therapeutic Product and Solutions
2.9.4 GlaxoSmithKline plc Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 GlaxoSmithKline plc Recent Developments and Future Plans
2.10 Amgen Inc.
2.10.1 Amgen Inc. Details
2.10.2 Amgen Inc. Major Business
2.10.3 Amgen Inc. Fabry Disease Therapeutic Product and Solutions
2.10.4 Amgen Inc. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Amgen Inc. Recent Developments and Future Plans
2.11 Teva pharmaceutical Industries Ltd.
2.11.1 Teva pharmaceutical Industries Ltd. Details
2.11.2 Teva pharmaceutical Industries Ltd. Major Business
2.11.3 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Product and Solutions
2.11.4 Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Teva pharmaceutical Industries Ltd. Recent Developments and Future Plans
2.12 Merc & Co.
2.12.1 Merc & Co. Details
2.12.2 Merc & Co. Major Business
2.12.3 Merc & Co. Fabry Disease Therapeutic Product and Solutions
2.12.4 Merc & Co. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Merc & Co. Recent Developments and Future Plans
2.13 AbbVie Inc.
2.13.1 AbbVie Inc. Details
2.13.2 AbbVie Inc. Major Business
2.13.3 AbbVie Inc. Fabry Disease Therapeutic Product and Solutions
2.13.4 AbbVie Inc. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.13.5 AbbVie Inc. Recent Developments and Future Plans
2.14 Takeda Pharmaceutical Co. Ltd.
2.14.1 Takeda Pharmaceutical Co. Ltd. Details
2.14.2 Takeda Pharmaceutical Co. Ltd. Major Business
2.14.3 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Product and Solutions
2.14.4 Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.14.5 Takeda Pharmaceutical Co. Ltd. Recent Developments and Future Plans
2.15 Green Cross Corp.
2.15.1 Green Cross Corp. Details
2.15.2 Green Cross Corp. Major Business
2.15.3 Green Cross Corp. Fabry Disease Therapeutic Product and Solutions
2.15.4 Green Cross Corp. Fabry Disease Therapeutic Revenue, Gross Margin and Market Share (2019-2021)
2.15.5 Green Cross Corp. Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Fabry Disease Therapeutic Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Fabry Disease Therapeutic Players Market Share
3.2.2 Top 10 Fabry Disease Therapeutic Players Market Share
3.2.3 Market Competition Trend
3.3 Fabry Disease Therapeutic Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Fabry Disease Therapeutic Revenue and Market Share by Type (2016-2021)
4.2 Global Fabry Disease Therapeutic Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Fabry Disease Therapeutic Revenue Market Share by Application (2016-2021)
5.2 Fabry Disease Therapeutic Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Fabry Disease Therapeutic Revenue by Type (2016-2026)
6.2 North America Fabry Disease Therapeutic Revenue by Application (2016-2026)
6.3 North America Fabry Disease Therapeutic Market Size by Country
6.3.1 North America Fabry Disease Therapeutic Revenue by Country (2016-2026)
6.3.2 United States Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
6.3.3 Canada Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
6.3.4 Mexico Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Fabry Disease Therapeutic Revenue by Type (2016-2026)
7.2 Europe Fabry Disease Therapeutic Revenue by Application (2016-2026)
7.3 Europe Fabry Disease Therapeutic Market Size by Country
7.3.1 Europe Fabry Disease Therapeutic Revenue by Country (2016-2026)
7.3.2 Germany Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
7.3.3 France Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
7.3.5 Russia Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
7.3.6 Italy Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Fabry Disease Therapeutic Revenue by Type (2016-2026)
8.2 Asia-Pacific Fabry Disease Therapeutic Revenue by Application (2016-2026)
8.3 Asia-Pacific Fabry Disease Therapeutic Market Size by Region
8.3.1 Asia-Pacific Fabry Disease Therapeutic Revenue by Region (2016-2026)
8.3.2 China Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
8.3.3 Japan Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
8.3.4 South Korea Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
8.3.5 India Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
8.3.7 Australia Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Fabry Disease Therapeutic Revenue by Type (2016-2026)
9.2 South America Fabry Disease Therapeutic Revenue by Application (2016-2026)
9.3 South America Fabry Disease Therapeutic Market Size by Country
9.3.1 South America Fabry Disease Therapeutic Revenue by Country (2016-2026)
9.3.2 Brazil Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
9.3.3 Argentina Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Fabry Disease Therapeutic Revenue by Type (2016-2026)
10.2 Middle East & Africa Fabry Disease Therapeutic Revenue by Application (2016-2026)
10.3 Middle East & Africa Fabry Disease Therapeutic Market Size by Country
10.3.1 Middle East & Africa Fabry Disease Therapeutic Revenue by Country (2016-2026)
10.3.2 Turkey Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
10.3.4 UAE Fabry Disease Therapeutic Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Fabry Disease Therapeutic Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Fabry Disease Therapeutic Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Fabry Disease Therapeutic Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Fabry Disease Therapeutic Revenue (USD Million) by Region (2016-2021)
Table 5. Global Fabry Disease Therapeutic Revenue Market Share by Region (2021-2026)
Table 6. Amicus therapeutics Corporate Information, Head Office, and Major Competitors
Table 7. Amicus therapeutics Major Business
Table 8. Amicus therapeutics Fabry Disease Therapeutic Product and Solutions
Table 9. Amicus therapeutics Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Takeda Corporate Information, Head Office, and Major Competitors
Table 11. Takeda Major Business
Table 12. Takeda Fabry Disease Therapeutic Product and Solutions
Table 13. Takeda Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Genzyme-Sanofi Corporate Information, Head Office, and Major Competitors
Table 15. Genzyme-Sanofi Major Business
Table 16. Genzyme-Sanofi Fabry Disease Therapeutic Product and Solutions
Table 17. Genzyme-Sanofi Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Protalix Corporate Information, Head Office, and Major Competitors
Table 19. Protalix Major Business
Table 20. Protalix Fabry Disease Therapeutic Product and Solutions
Table 21. Protalix Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Sanofi-Aventis LLC Corporate Information, Head Office, and Major Competitors
Table 23. Sanofi-Aventis LLC Major Business
Table 24. Sanofi-Aventis LLC Fabry Disease Therapeutic Product and Solutions
Table 25. Sanofi-Aventis LLC Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Novartis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Pharmaceuticals Major Business
Table 28. Novartis Pharmaceuticals Fabry Disease Therapeutic Product and Solutions
Table 29. Novartis Pharmaceuticals Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Pfizer Corporate Information, Head Office, and Major Competitors
Table 31. Pfizer Major Business
Table 32. Pfizer Fabry Disease Therapeutic Product and Solutions
Table 33. Pfizer Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Bristol-Myers Squibb Company Corporate Information, Head Office, and Major Competitors
Table 35. Bristol-Myers Squibb Company Major Business
Table 36. Bristol-Myers Squibb Company Fabry Disease Therapeutic Product and Solutions
Table 37. Bristol-Myers Squibb Company Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. GlaxoSmithKline plc Corporate Information, Head Office, and Major Competitors
Table 39. GlaxoSmithKline plc Major Business
Table 40. GlaxoSmithKline plc Fabry Disease Therapeutic Product and Solutions
Table 41. GlaxoSmithKline plc Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Amgen Inc. Corporate Information, Head Office, and Major Competitors
Table 43. Amgen Inc. Major Business
Table 44. Amgen Inc. Fabry Disease Therapeutic Product and Solutions
Table 45. Amgen Inc. Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Teva pharmaceutical Industries Ltd. Corporate Information, Head Office, and Major Competitors
Table 47. Teva pharmaceutical Industries Ltd. Major Business
Table 48. Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Product and Solutions
Table 49. Teva pharmaceutical Industries Ltd. Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Merc & Co. Corporate Information, Head Office, and Major Competitors
Table 51. Merc & Co. Major Business
Table 52. Merc & Co. Fabry Disease Therapeutic Product and Solutions
Table 53. Merc & Co. Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. AbbVie Inc. Corporate Information, Head Office, and Major Competitors
Table 55. AbbVie Inc. Major Business
Table 56. AbbVie Inc. Fabry Disease Therapeutic Product and Solutions
Table 57. AbbVie Inc. Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 58. Takeda Pharmaceutical Co. Ltd. Corporate Information, Head Office, and Major Competitors
Table 59. Takeda Pharmaceutical Co. Ltd. Major Business
Table 60. Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Product and Solutions
Table 61. Takeda Pharmaceutical Co. Ltd. Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 62. Green Cross Corp. Corporate Information, Head Office, and Major Competitors
Table 63. Green Cross Corp. Major Business
Table 64. Green Cross Corp. Fabry Disease Therapeutic Product and Solutions
Table 65. Green Cross Corp. Fabry Disease Therapeutic Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 66. Global Fabry Disease Therapeutic Revenue (USD Million) by Players (2019-2021)
Table 67. Global Fabry Disease Therapeutic Revenue Share by Players (2019-2021)
Table 68. Breakdown of Fabry Disease Therapeutic by Company Type (Tier 1, Tier 2 and Tier 3)
Table 69. Fabry Disease Therapeutic Players Head Office, Products and Services Provided
Table 70. Fabry Disease Therapeutic Mergers & Acquisitions in the Past Five Years
Table 71. Fabry Disease Therapeutic New Entrants and Expansion Plans
Table 72. Global Fabry Disease Therapeutic Revenue (USD Million) by Type (2016-2021)
Table 73. Global Fabry Disease Therapeutic Revenue Share by Type (2016-2021)
Table 74. Global Fabry Disease Therapeutic Revenue Forecast by Type (2021-2026)
Table 75. Global Fabry Disease Therapeutic Revenue by Application (2016-2021)
Table 76. Global Fabry Disease Therapeutic Revenue Forecast by Application (2021-2026)
Table 77. North America Fabry Disease Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 78. North America Fabry Disease Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 79. North America Fabry Disease Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 80. North America Fabry Disease Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 81. North America Fabry Disease Therapeutic Revenue by Country (2016-2021) & (USD Million)
Table 82. North America Fabry Disease Therapeutic Revenue by Country (2021-2026) & (USD Million)
Table 83. Europe Fabry Disease Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 84. Europe Fabry Disease Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 85. Europe Fabry Disease Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 86. Europe Fabry Disease Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 87. Europe Fabry Disease Therapeutic Revenue by Country (2016-2021) & (USD Million)
Table 88. Europe Fabry Disease Therapeutic Revenue by Country (2021-2026) & (USD Million)
Table 89. Asia-Pacific Fabry Disease Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 90. Asia-Pacific Fabry Disease Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 91. Asia-Pacific Fabry Disease Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 92. Asia-Pacific Fabry Disease Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 93. Asia-Pacific Fabry Disease Therapeutic Revenue by Region (2016-2021) & (USD Million)
Table 94. Asia-Pacific Fabry Disease Therapeutic Revenue by Region (2021-2026) & (USD Million)
Table 95. South America Fabry Disease Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 96. South America Fabry Disease Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 97. South America Fabry Disease Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 98. South America Fabry Disease Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 99. South America Fabry Disease Therapeutic Revenue by Country (2016-2021) & (USD Million)
Table 100. South America Fabry Disease Therapeutic Revenue by Country (2021-2026) & (USD Million)
Table 101. Middle East & Africa Fabry Disease Therapeutic Revenue by Type (2016-2021) & (USD Million)
Table 102. Middle East & Africa Fabry Disease Therapeutic Revenue by Type (2021-2026) & (USD Million)
Table 103. Middle East & Africa Fabry Disease Therapeutic Revenue by Application (2016-2021) & (USD Million)
Table 104. Middle East & Africa Fabry Disease Therapeutic Revenue by Application (2021-2026) & (USD Million)
Table 105. Middle East & Africa Fabry Disease Therapeutic Revenue by Country (2016-2021) & (USD Million)
Table 106. Middle East & Africa Fabry Disease Therapeutic Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Fabry Disease Therapeutic Picture
Figure 2. Global Fabry Disease Therapeutic Revenue Market Share by Type in 2020
Figure 3. Enzyme Replacement Therapy
Figure 4. Alternative therapies
Figure 5. Fabry Disease Therapeutic Revenue Market Share by Application in 2020
Figure 6. Hospitals Picture
Figure 7. Clinics Picture
Figure 8. Other Picture
Figure 9. Global Fabry Disease Therapeutic Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Fabry Disease Therapeutic Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Fabry Disease Therapeutic Revenue Market Share by Region (2016-2026)
Figure 12. Global Fabry Disease Therapeutic Revenue Market Share by Region in 2020
Figure 13. North America Fabry Disease Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Fabry Disease Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Fabry Disease Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Fabry Disease Therapeutic Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Fabry Disease Therapeutic Market Drivers
Figure 18. Fabry Disease Therapeutic Market Restraints
Figure 19. Fabry Disease Therapeutic Market Trends
Figure 20. Amicus therapeutics Recent Developments and Future Plans
Figure 21. Takeda Recent Developments and Future Plans
Figure 22. Genzyme-Sanofi Recent Developments and Future Plans
Figure 23. Protalix Recent Developments and Future Plans
Figure 24. Sanofi-Aventis LLC Recent Developments and Future Plans
Figure 25. Novartis Pharmaceuticals Recent Developments and Future Plans
Figure 26. Pfizer Recent Developments and Future Plans
Figure 27. Bristol-Myers Squibb Company Recent Developments and Future Plans
Figure 28. GlaxoSmithKline plc Recent Developments and Future Plans
Figure 29. Amgen Inc. Recent Developments and Future Plans
Figure 30. Teva pharmaceutical Industries Ltd. Recent Developments and Future Plans
Figure 31. Merc & Co. Recent Developments and Future Plans
Figure 32. AbbVie Inc. Recent Developments and Future Plans
Figure 33. Takeda Pharmaceutical Co. Ltd. Recent Developments and Future Plans
Figure 34. Green Cross Corp. Recent Developments and Future Plans
Figure 36. Global Fabry Disease Therapeutic Revenue Share by Players in 2020
Figure 37. Fabry Disease Therapeutic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 38. Global Top 3 Players Fabry Disease Therapeutic Revenue Market Share in 2020
Figure 39. Global Top 10 Players Fabry Disease Therapeutic Revenue Market Share in 2020
Figure 40. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 41. Global Fabry Disease Therapeutic Revenue Share by Type in 2020
Figure 42. Global Fabry Disease Therapeutic Market Share Forecast by Type (2021-2026)
Figure 43. Global Fabry Disease Therapeutic Revenue Share by Application in 2020
Figure 44. Global Fabry Disease Therapeutic Market Share Forecast by Application (2021-2026)
Figure 45. North America Fabry Disease Therapeutic Sales Market Share by Type (2016-2026)
Figure 46. North America Fabry Disease Therapeutic Sales Market Share by Application (2016-2026)
Figure 47. North America Fabry Disease Therapeutic Revenue Market Share by Country (2016-2026)
Figure 48. United States Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Canada Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Mexico Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Europe Fabry Disease Therapeutic Sales Market Share by Type (2016-2026)
Figure 52. Europe Fabry Disease Therapeutic Sales Market Share by Application (2016-2026)
Figure 53. Europe Fabry Disease Therapeutic Revenue Market Share by Country (2016-2026)
Figure 54. Germany Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. France Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. United Kingdom Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Russia Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Italy Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Asia-Pacific Fabry Disease Therapeutic Sales Market Share by Type (2016-2026)
Figure 60. Asia-Pacific Fabry Disease Therapeutic Sales Market Share by Application (2016-2026)
Figure 61. Asia-Pacific Fabry Disease Therapeutic Revenue Market Share by Region (2016-2026)
Figure 62. China Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Japan Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. South Korea Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. India Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Southeast Asia Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Australia Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. South America Fabry Disease Therapeutic Sales Market Share by Type (2016-2026)
Figure 69. South America Fabry Disease Therapeutic Sales Market Share by Application (2016-2026)
Figure 70. South America Fabry Disease Therapeutic Revenue Market Share by Country (2016-2026)
Figure 71. Brazil Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Argentina Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 73. Middle East and Africa Fabry Disease Therapeutic Sales Market Share by Type (2016-2026)
Figure 74. Middle East and Africa Fabry Disease Therapeutic Sales Market Share by Application (2016-2026)
Figure 75. Middle East and Africa Fabry Disease Therapeutic Revenue Market Share by Country (2016-2026)
Figure 76. Turkey Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. Saudi Arabia Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. UAE Fabry Disease Therapeutic Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 79. Methodology
Figure 80. Research Process and Data Source
世界のファブリー病治療市場 2021：企業別、地域別、種類・用途別 The Fabry Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulat…- ファブリー病治療薬の世界市場2020年：分析と予測（～2025年） This report describes the global market size of Fabry Disease Drugs from 2015 to 2019 and its CAGR from 2015 to 2019, and also forecasts its market size to the end of 2025 and its CAGR from 2020 to 2025. For geography segment, regional supply, demand, major players, price is presented from 2015 to 2…
- 世界のクローン病診断・治療市場規模・現状・予測（2021年-2027年） Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals. Market Analysis and Insights: Global Crohn…
- 世界のクローン病診断・治療市場規模・現状・予測（2021年-2027年） Crohn’s disease (CD) is an inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to the anus. It is caused by a combination of environmental, immune, and bacterial factors, in genetically predisposed individuals. Market Analysis and Insights: Global Crohn…
- 世界の腸疾患検査・治療市場規模・現状・予測（2021年-2027年） Enteric diseases are the infections caused by ingestion of contaminated food or water. These infections are commonly caused by bacteria and viruses. Poor maintenance of hygiene and sanitation, particularly due to rising population and urbanization is increasing the prevalence of enteric diseases. Ac…